{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:28:54Z","timestamp":1774992534303,"version":"3.50.1"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.leukres.2019.04.001","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T19:06:00Z","timestamp":1554404760000},"page":"10-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Relevant updates in systemic mastocytosis"],"prefix":"10.1016","volume":"81","author":[{"given":"Alexander","family":"Coltoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.leukres.2019.04.001_bib0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/j.leukres.2019.04.001_bib0010","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.clml.2015.07.644","article-title":"Systemic mastocytosis: clinical update and future directions","volume":"15","author":"Tremblay","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2019.04.001_bib0015","first-page":"166","article-title":"Beitrage zur Kenntnis der granulierten. Bindegewebszellen und der eosinophilen Leukozyten","volume":"3","author":"Ehrlich","year":"1879","journal-title":"Arch. Anat. Physiol."},{"issue":"50","key":"10.1016\/j.leukres.2019.04.001_bib0020","doi-asserted-by":"crossref","first-page":"18105","DOI":"10.1073\/pnas.0509148102","article-title":"Developmental checkpoints of the basophil\/mast cell lineages in adult murine hematopoiesis","volume":"102","author":"Arinobu","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.leukres.2019.04.001_bib0025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.immuni.2013.06.012","article-title":"Antagonistic regulation by the transcription factors C\/EBP\u03b1 and MITF specifies basophil and mast cell fates","volume":"39","author":"Qi","year":"2013","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.leukres.2019.04.001_bib0030","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2567.2007.02705.x","article-title":"Neuropeptides activate human mast cell degranulation and chemokine production","volume":"123","author":"Kulka","year":"2008","journal-title":"Immunology"},{"issue":"26","key":"10.1016\/j.leukres.2019.04.001_bib0035","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","article-title":"Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis","volume":"316","author":"Schwartz","year":"1987","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2019.04.001_bib0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.molimm.2014.06.018","article-title":"The role of the IL-33\/IL-1RL1 axis in mast cell and basophil activation in allergic disorders","volume":"63","author":"Saluja","year":"2015","journal-title":"Mol. Immunol."},{"issue":"2","key":"10.1016\/j.leukres.2019.04.001_bib0045","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ajpath.2015.07.025","article-title":"The mast cell-IgE paradox: from homeostasis to anaphylaxis","volume":"186","author":"Galli","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.leukres.2019.04.001_bib0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.leukres.2019.04.001_bib0055","first-page":"323","article-title":"Rare forms of urticaria","volume":"2","author":"Nettleship","year":"1869","journal-title":"Br. Med. J."},{"key":"10.1016\/j.leukres.2019.04.001_bib0060","first-page":"161","article-title":"An anomalous mottled rash, accompanied by pruritus factitious urticaria and pigmentation,\u2019urticaria pigmentosa (?)\u2019","volume":"11","author":"Sangster","year":"1878","journal-title":"Trans. Clin. Soc. London"},{"key":"10.1016\/j.leukres.2019.04.001_bib0065","first-page":"9","article-title":"Beitrage zur Anatomie und Pathogenese der Urticaria simplex und pigmentosa","volume":"3","author":"Unna","year":"1887","journal-title":"Monatschr. Prakt. Dermatol."},{"key":"10.1016\/j.leukres.2019.04.001_bib0070","first-page":"359","article-title":"Dermographisme et mastocytose","volume":"43","author":"Sezary","year":"1936","journal-title":"Bull. Soc. Fr. Dermatol. Syphiligr."},{"issue":"5","key":"10.1016\/j.leukres.2019.04.001_bib0075","first-page":"426","article-title":"Urticaria pigmentosa; a report of a case with autopsy","volume":"48","author":"Ellis","year":"1949","journal-title":"Arch. Pathol."},{"issue":"2","key":"10.1016\/j.leukres.2019.04.001_bib0080","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archderm.1963.01590140008002","article-title":"The natural course of urticaria pigmentosa: analysis and follow-up of 112 cases","volume":"87","author":"Caplan","year":"1963","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.leukres.2019.04.001_bib0085","article-title":"Mastocytosis 2016: updated WHO classification and novel emerging treatment concepts","author":"Valent","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2019.04.001_bib0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11588890-000000000-00000","article-title":"Diagnosis and treatment of cutaneous mastocytosis in children","volume":"12","author":"Castells","year":"2011","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.leukres.2019.04.001_bib0095","series-title":"Mastocytosis and the Mast Cell. Chicago","author":"Sagher","year":"1967"},{"key":"10.1016\/j.leukres.2019.04.001_bib0100","series-title":"Tratado de dermatolog\u00eda pedi\u00e1trica","author":"Ruiz-Maldonado","year":"1992"},{"issue":"9","key":"10.1016\/j.leukres.2019.04.001_bib0105","first-page":"461","article-title":"Diagn\u00f3stico, tratamiento y clasificaci\u00f3n de la mastocitosis pedi\u00e1trica. Estudio de 172 casos","volume":"89","author":"Torrelo Fern\u00e1ndez","year":"1998","journal-title":"Actas Dermo-sifiliogr\u00e3\u00a1ficas"},{"issue":"3","key":"10.1016\/j.leukres.2019.04.001_bib0110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1468-3083.2004.00830.x","article-title":"Cutaneous mastocytosis in children: a clinical analysis of 71 cases.\"","volume":"18","author":"Kiszewski","year":"2004","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"23","key":"10.1016\/j.leukres.2019.04.001_bib0115","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2019.04.001_bib0120","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","article-title":"Epidemiology, prognosis, and risk factors in mastocytosis","volume":"34","author":"Brockow","year":"2014","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"10.1016\/j.leukres.2019.04.001_bib0125","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0065-2776(05)89005-4","article-title":"Systemic mastocytosis","volume":"89","author":"Robyn","year":"2006","journal-title":"Adv. Immunol."},{"issue":"4","key":"10.1016\/j.leukres.2019.04.001_bib0130","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2019.04.001_bib0135","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fimmu.2014.00569","article-title":"Mast cell mediators: their differential release and the secretory pathways involved","volume":"5","author":"Moon","year":"2014","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.leukres.2019.04.001_bib0140","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1111\/1523-1747.ep12468899","article-title":"Systemic mastocytosis: retrospective review of a decade\u2019s clinical experience at the Brigham and Women\u2019s Hospital","volume":"96","author":"Horan","year":"1991","journal-title":"J. Invest. Dermatol."},{"issue":"10","key":"10.1016\/j.leukres.2019.04.001_bib0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026375","article-title":"Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy","volume":"6","author":"Moura","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.leukres.2019.04.001_bib0150","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2019.04.001_bib0155","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2019.04.001_bib0160","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2019.04.001_bib0165","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur. J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.leukres.2019.04.001_bib0170","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","article-title":"Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal","volume":"25","author":"Valent","year":"2014","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2019.04.001_bib0175","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.14967","article-title":"How we diagnose and treat systemic mastocytosis in adults","volume":"180","author":"Scherber","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.leukres.2019.04.001_bib0180","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10","key":"10.1016\/j.leukres.2019.04.001_bib0185","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1365-2222.2007.02804.x","article-title":"Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)","volume":"37","author":"Gonzalez de Olano","year":"2007","journal-title":"Clin. Exp. Allergy"},{"issue":"1","key":"10.1016\/j.leukres.2019.04.001_bib0190","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000436969","article-title":"Management of anesthesia in adult and pediatric mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) based on 726 anesthetic procedures","volume":"167","author":"Matito","year":"2015","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"8","key":"10.1016\/j.leukres.2019.04.001_bib0195","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1398-9995.1990.tb00945.x","article-title":"Mastocytosis and atopy: a study of 33 patients with urticaria pigmentosa","volume":"45","author":"M\u00fcller","year":"1990","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.leukres.2019.04.001_bib0200","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.leukres.2019.04.001_bib0205","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis","volume":"55","author":"Akin","year":"2004","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.leukres.2019.04.001_bib0210","first-page":"36","article-title":"Mastocytosis without urticaria pigmentosa: a frequently unrecognized cause of recurrent syncope","volume":"95","author":"Fields","year":"1982","journal-title":"Trans. Assoc. Am. Physicians"},{"issue":"7","key":"10.1016\/j.leukres.2019.04.001_bib0215","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0145-2126(01)00039-X","article-title":"Treatment of mastocytosis: pharmacologic basis and current concepts","volume":"25","author":"Marone","year":"2001","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.leukres.2019.04.001_bib0220","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0889-8588(05)70301-4","article-title":"Treatment of systemic mast cell disorders","volume":"14","author":"Worobec","year":"2000","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"3-4","key":"10.1016\/j.leukres.2019.04.001_bib0225","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.prostaglandins.2009.01.001","article-title":"Survey of aspirin administration in systemic mastocytosis","volume":"88","author":"Butterfield","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"1-4","key":"10.1016\/j.leukres.2019.04.001_bib0230","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.prostaglandins.2010.03.003","article-title":"Increased leukotriene E4 excretion in systemic mastocytosis","volume":"92","author":"Butterfield","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"2","key":"10.1016\/j.leukres.2019.04.001_bib0235","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1525-1470.2011.01576.x","article-title":"Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis","volume":"29","author":"Turner","year":"2012","journal-title":"Pediatr. Dermatol."},{"issue":"7","key":"10.1016\/j.leukres.2019.04.001_bib0240","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM200402123500723","article-title":"Leukotriene-receptor inhibition for the treatment of systemic mastocytosis","volume":"350","author":"Tolar","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2019.04.001_bib0245","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.leukres.2019.04.001_bib0250","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM197908303010903","article-title":"Oral disodium cromoglycate in the treatment of systemic mastocytosis","volume":"301","author":"Soter","year":"1979","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.leukres.2019.04.001_bib0255","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaip.2014.03.009","article-title":"Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report","volume":"2","author":"Sokol","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"6","key":"10.1016\/j.leukres.2019.04.001_bib0260","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.leukres.2019.04.001_bib0265","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00414106","article-title":"Phototherapy of urticaria pigmentosa: clinical response and changes of cutaneous reactivity, histamine and chemotactic leukotrienes","volume":"277","author":"Czarnetzki","year":"1985","journal-title":"Arch. Dermatol. Res."},{"issue":"8","key":"10.1016\/j.leukres.2019.04.001_bib0270","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1365-2230.2010.03825.x","article-title":"Cutaneous mastocytosis: successful treatment with narrowband ultraviolet B phototherapy","volume":"35","author":"Prignano","year":"2010","journal-title":"Clin. Exp. Dermatol.: Viewpoints Dermatol."},{"issue":"4","key":"10.1016\/j.leukres.2019.04.001_bib0275","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00000421-199408000-00009","article-title":"Radiotherapy of refractory bone pain due to systemic mast cell disease","volume":"17","author":"Johnstone","year":"1994","journal-title":"Am. J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2019.04.001_bib0280","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients","volume":"69","author":"Barete","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.leukres.2019.04.001_bib0285","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/rheumatology\/36.3.393","article-title":"The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis","volume":"36","author":"Marshall","year":"1997","journal-title":"Br. J. Rheumatol."},{"issue":"3","key":"10.1016\/j.leukres.2019.04.001_bib0290","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/8756-3282(87)90014-7","article-title":"Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption","volume":"8","author":"Cundy","year":"1987","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.leukres.2019.04.001_bib0295","doi-asserted-by":"crossref","first-page":"e76116","DOI":"10.1371\/journal.pone.0076116","article-title":"Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome","volume":"8","author":"Matito","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.leukres.2019.04.001_bib0300","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2014","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2019.04.001_bib0305","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000048185","article-title":"Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression","volume":"127","author":"Valent","year":"2002","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.leukres.2019.04.001_bib0310","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","author":"Valent","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2019.04.001_bib0315","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.leukres.2019.04.001_bib0320","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon\u2010\u03b1: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2019.04.001_bib0325","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon\u2010alpha, hydroxyurea, imatinib mesylate or 2\u2010chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2019.04.001_bib0330","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.leukres.2019.04.001_bib0335","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.04.001_bib0340","series-title":"Long Term Efficacy and Safety of Cladribine in Adult Systemic Mastocytosis: A French Multicenter Study of 44 Patients","author":"Hermine","year":"2010"},{"issue":"9","key":"10.1016\/j.leukres.2019.04.001_bib0345","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.leukres.2019.04.001_bib0350","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.10.020","article-title":"Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes","volume":"125","author":"Teodosio","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.leukres.2019.04.001_bib0355","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1053\/gast.2002.33024","article-title":"Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene","volume":"122","author":"Hirota","year":"2002","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.leukres.2019.04.001_bib0360","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.leukres.2019.04.001_bib0365","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.leukres.2019.04.001_bib0370","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.leukres.2019.04.001_bib0375","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.leukres.2019.04.001_bib0380","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase ii study of dasatinib in Philadelphia chromosome\u2013negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2019.04.001_bib0385","series-title":"A Phase II Study of Nilotinib, a Novel Inhibitor of c-Kit, PDGFR, and Bcr-Abl, Administered to Patients with Systemic Mastocytosis","author":"Hochhaus","year":"2006"},{"issue":"2","key":"10.1016\/j.leukres.2019.04.001_bib0390","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/blood-2017-05-781237","article-title":"A molecular roadmap for midostaurin in mastocytosis","volume":"130","author":"Gotlib","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2019.04.001_bib0395","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2019.04.001_bib0400","series-title":"KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial","author":"Gotlib","year":"2010"},{"issue":"3","key":"10.1016\/j.leukres.2019.04.001_bib0405","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial","volume":"142","author":"van Anrooij","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10069","key":"10.1016\/j.leukres.2019.04.001_bib0410","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.leukres.2019.04.001_bib0415","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/jcp.2003.014860","article-title":"Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge","volume":"57","author":"Horny","year":"2004","journal-title":"J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.leukres.2019.04.001_bib0420","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MOH.0b013e3283366c59","article-title":"Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature","volume":"17","author":"Pardanani","year":"2010","journal-title":"Curr. Opin. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2019.04.001_bib0425","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000048186","article-title":"Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis","volume":"127","author":"Sperr","year":"2002","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"29","key":"10.1016\/j.leukres.2019.04.001_bib0430","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"5-6","key":"10.1016\/j.leukres.2019.04.001_bib0435","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/10428199609054789","article-title":"Treatment of three patients with systemic mastocytosis with interferon alpha-2b","volume":"22","author":"Worobec","year":"1996","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.leukres.2019.04.001_bib0440","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1365-2133.1998.02131.x","article-title":"Response of severe systemic mastocytosis to interferon alpha","volume":"138","author":"Butterfield","year":"1998","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.leukres.2019.04.001_bib0445","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(03)00185-1","article-title":"Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine","volume":"28","author":"Pardanani","year":"2004","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2019.04.001_bib0450","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","author":"Barete","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2019.04.001_bib0455","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2362.2008.02036.x","article-title":"Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis","volume":"38","author":"Aichberger","year":"2008","journal-title":"Eur. J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.leukres.2019.04.001_bib0460","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","article-title":"Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"4","key":"10.1016\/j.leukres.2019.04.001_bib0465","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bmt.1705245","article-title":"A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis","volume":"37","author":"Nakamura","year":"2006","journal-title":"Bone Marrow Transplant."},{"issue":"8","key":"10.1016\/j.leukres.2019.04.001_bib0470","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Georgin-Lavialle","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.04.001_bib0475","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.leukres.2017.05.018","article-title":"Mast cell leukemia (MCL): clinico-pathologic and molecular features and survival outcome","volume":"59","author":"Jain","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2019.04.001_bib0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2014.09.010","article-title":"Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features","volume":"39","author":"Valent","year":"2015","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.leukres.2019.04.001_bib0485","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00277-007-0430-3","article-title":"Mast cell leukemia: a report of ten cases","volume":"87","author":"Valentini","year":"2008","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2019.04.001_bib0490","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1525-1470.2011.01650.x","article-title":"Death from mast cell leukemia: a young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia","volume":"29","author":"Chantorn","year":"2012","journal-title":"Pediatr. Dermatol."},{"issue":"2","key":"10.1016\/j.leukres.2019.04.001_bib0495","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"issue":"47","key":"10.1016\/j.leukres.2019.04.001_bib0500","doi-asserted-by":"crossref","first-page":"82897","DOI":"10.18632\/oncotarget.19970","article-title":"Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia","volume":"8","author":"Kampa-Schittenhelm","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2019.04.001_bib0505","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.2230.2230","article-title":"Gain-of-function KIT mutations sensitize the mutant isoform to the type I tyrosine kinase inhibitor crenolanib: a rationale for the therapeutic use in systemic mastocytosis (SM) and core binding factor leukemias (CBFL)","author":"Schittenhelm","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.04.001_bib0510","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7008","article-title":"Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2019.04.001_bib0515","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3217.3217","article-title":"First selective KIT D816V inhibitor for patients with systemic mastocytosis","author":"Evans","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.04.001_bib0520","article-title":"Avapritinib (BLU-285), a selective KIT inhibitor, is associated with high response rate and tolerable safety profile in advanced systemic mastocytosis: results of a phase 1 study","volume":"6","author":"Deininger","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.leukres.2019.04.001_bib0525","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1965.1965","article-title":"The multi-kinase inhibitor DCC-2618 inhibits proliferation and survival of neoplastic mast cells and other cell types involved in systemic mastocytosis","author":"Schneeweiss","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.04.001_bib0530","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.2515","article-title":"Pharmacokinetic-driven phase I study of DCC-2618 a pan-KIT and PDGFR inhibitor in patients (pts) with gastrointestinal stromal tumor (GIST) and other solid tumors","author":"Janku","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2019.04.001_bib0535","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4245.4245","article-title":"Results from ongoing phase 2 trial of SL-401 in patients with advanced, high-risk myeloproliferative neoplasms including chronic myelomonocytic leukemia","author":"Patnaik","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2019.04.001_bib0540","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/leu.2015.16","article-title":"Aberrant expression of CD123 (interleukin-3 receptor-\u03b1) on neoplastic mast cells","volume":"29","author":"Pardanani","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2019.04.001_bib0545","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/his.12221","article-title":"CD 30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis","volume":"63","author":"Morgado","year":"2013","journal-title":"Histopathology"},{"issue":"May 44","key":"10.1016\/j.leukres.2019.04.001_bib0550","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.leukres.2016.02.010","article-title":"Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin","volume":"1","author":"Borate","year":"2016","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2019.04.001_bib0555","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.leukres.2016.02.010","article-title":"Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin","volume":"44","author":"Borate","year":"2016","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.leukres.2019.04.001_bib0560","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/leu.2017.183","article-title":"SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis","volume":"32","author":"Martinelli","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2019.04.001_bib0565","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/ejh.12606","article-title":"Successful treatment of mast cell activation syndrome with sunitinib","volume":"95","author":"Afrin","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2019.04.001_bib0570","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.13343.1","article-title":"Case report: treatment of systemic mastocytosis with sunitinib","volume":"6","author":"Molderings","year":"2017","journal-title":"F1000Research"},{"issue":"3","key":"10.1016\/j.leukres.2019.04.001_bib0575","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/bloodadvances.2017011551","article-title":"Variability of PD-L1 expression in mastocytosis","volume":"2","author":"Hatch","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2019.04.001_bib0580","doi-asserted-by":"crossref","DOI":"10.1111\/cea.13217","article-title":"The JAK1\/JAK2\u2010inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release","author":"Hermans","year":"2018","journal-title":"Clin. Exp. Allergy"},{"issue":"1","key":"10.1016\/j.leukres.2019.04.001_bib0585","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40364-016-0056-5","article-title":"Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis","volume":"4","author":"Yacoub","year":"2016","journal-title":"Biomark. Res."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619300566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:59:30Z","timestamp":1758934770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619300566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":117,"alternative-id":["S0145212619300566"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.04.001","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relevant updates in systemic mastocytosis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}